SVB Leerink Increases Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $230.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target upped by SVB Leerink from $165.00 to $230.00 in a report released on Monday morning, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

A number of other research firms have also commented on SRPT. Robert W. Baird increased their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a research report on Friday, June 21st. Citigroup increased their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a research report on Thursday, February 29th. Barclays increased their price target on Sarepta Therapeutics from $185.00 to $226.00 and gave the stock an overweight rating in a research report on Friday, June 21st. Mizuho increased their price target on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a buy rating in a research report on Friday, May 17th. Finally, UBS Group increased their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a buy rating in a research report on Friday, March 1st. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average target price of $185.06.

Sarepta Therapeutics Trading Down 0.7 %

SRPT stock opened at $156.91 on Monday. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The firm has a market cap of $14.83 billion, a P/E ratio of 1,426.45 and a beta of 0.96. The business’s 50 day moving average is $128.07 and its 200-day moving average is $121.46. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. During the same period in the prior year, the company posted ($1.44) EPS. The company’s revenue was up 63.1% compared to the same quarter last year. Equities analysts anticipate that Sarepta Therapeutics will post 3.71 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. Insiders have sold a total of 50,451 shares of company stock valued at $8,086,386 in the last 90 days. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Principal Securities Inc. acquired a new stake in Sarepta Therapeutics during the 4th quarter worth $26,000. Mather Group LLC. acquired a new stake in Sarepta Therapeutics during the 1st quarter worth $28,000. Riggs Asset Managment Co. Inc. raised its stake in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the period. Cary Street Partners Investment Advisory LLC increased its holdings in Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Finally, New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics during the 1st quarter worth about $32,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.